Takahiro Ishii1, Akihito Kawazoe1, Kohei Shitara2. 1. Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. 2. Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. kshitara@east.ncc.go.jp.
Abstract
BACKGROUND: In recent years, a better understanding of tumor biology and molecular features of gastric cancer has been reached. It may serve as a roadmap for patient stratification and trials of targeted therapies. The apparent efficacy of PD-1 blockade might be limited to a relatively small subset of advanced gastric cancer patients. MATERIALS AND METHODS: In this study, preclinical and clinical studies, which investigated molecular features, promising treatment targets, and immune checkpoint inhibitor in gastric cancer, were reviewed via PubMed and the congress webpages of the American Society of Clinical Oncology and European Society of Medical Oncology. RESULTS: Next-generation sequencing technologies have defined the genomic landscape of gastric cancer. Indeed, several molecular classifications have been proposed, and distinct molecular subtypes have been identified. Based on these molecular profiles, clinical trials of new agents such as receptor tyrosine kinases inhibitors, antibody-drug conjugates, and IMAB362 (anti-Claudin 18.2) are ongoing. In addition, biomarkers to predict response during immune checkpoint inhibitors and combination therapy have been enthusiastically investigated. CONCLUSION: Remarkable advances in an understanding of molecular profiles of gastric cancer enable the development of novel agents. The better treatment selection of immune checkpoint inhibitors or combination therapy should be established. These developments could facilitate precision medicine on gastric cancer in the near future.
BACKGROUND: In recent years, a better understanding of tumor biology and molecular features of gastric cancer has been reached. It may serve as a roadmap for patient stratification and trials of targeted therapies. The apparent efficacy of PD-1 blockade might be limited to a relatively small subset of advanced gastric cancerpatients. MATERIALS AND METHODS: In this study, preclinical and clinical studies, which investigated molecular features, promising treatment targets, and immune checkpoint inhibitor in gastric cancer, were reviewed via PubMed and the congress webpages of the American Society of Clinical Oncology and European Society of Medical Oncology. RESULTS: Next-generation sequencing technologies have defined the genomic landscape of gastric cancer. Indeed, several molecular classifications have been proposed, and distinct molecular subtypes have been identified. Based on these molecular profiles, clinical trials of new agents such as receptor tyrosine kinases inhibitors, antibody-drug conjugates, and IMAB362 (anti-Claudin 18.2) are ongoing. In addition, biomarkers to predict response during immune checkpoint inhibitors and combination therapy have been enthusiastically investigated. CONCLUSION: Remarkable advances in an understanding of molecular profiles of gastric cancer enable the development of novel agents. The better treatment selection of immune checkpoint inhibitors or combination therapy should be established. These developments could facilitate precision medicine on gastric cancer in the near future.
Authors: Elisabete Fernandes; Rui Freitas; Dylan Ferreira; Janine Soares; Rita Azevedo; Cristiana Gaiteiro; Andreia Peixoto; Sara Oliveira; Sofia Cotton; Marta Relvas-Santos; Luis Pedro Afonso; Carlos Palmeira; Maria José Oliveira; Rita Ferreira; André M N Silva; Lúcio Lara Santos; José Alexandre Ferreira Journal: Cancers (Basel) Date: 2020-04-02 Impact factor: 6.639
Authors: Deniz Bakkalci; Yumeng Jia; Joanne R Winter; Joanna Ea Lewis; Graham S Taylor; Helen R Stagg Journal: J Glob Health Date: 2020-06 Impact factor: 4.413
Authors: Philipp Rhode; Matthias Mehdorn; Orestis Lyros; Christoph Kahlert; Thomas Kurth; Tom Venus; Katrin Schierle; Irina Estrela-Lopis; Boris Jansen-Winkeln; Florian Lordick; Ines Gockel; René Thieme Journal: Cancers (Basel) Date: 2021-11-27 Impact factor: 6.639